TPST
Tempest Therapeutics, Inc. (TPST) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
TPST lacks disclosed 5-year revenue, EPS, or FCF CAGR data, limiting evidence of repeatable compounding versus peers with established multi-year growth records.
Negative TTM ROIC suggests current capital deployment is not yet generating scalable returns, reducing confidence that reinvestment can translate into durable revenue expansion.
Zero reported capex-to-revenue and R&D-to-revenue metrics imply limited visible reinvestment intensity, which weakens the case for sustained internal growth versus better-funded peers.
The absence of segment concentration data makes it harder to identify a scalable revenue engine, leaving TPST behind peers with clearer product or customer expansion pathways.
Market Tailwinds
No filing-based evidence here shows TPST benefiting from a durable demand tailwind, while peers with validated commercial traction can compound from clearer market pull.
The available metrics do not demonstrate expanding addressable revenue channels, so long-term growth appears more dependent on execution than on proven external demand support.
Negative profitability and missing growth history suggest any market opportunity has not yet translated into durable revenue scaling, unlike stronger peers with visible adoption curves.
Without segment or customer data, TPST cannot be shown to have the same multi-year demand visibility that supports higher-growth peer profiles.
Scalability Expansion
TPST’s negative ROIC indicates weak scaling efficiency, meaning incremental capital has not yet produced the kind of compounding seen in more scalable peers.
The negative cash conversion cycle is operationally favorable, but it does not offset the lack of evidence that the business can expand revenue at scale.
No disclosed share-count growth, margin trend, or segment expansion data limits proof that the company can reinvest and grow without proportional resource increases.
Compared with peers that show recurring revenue expansion and improving unit economics, TPST currently lacks demonstrated operating leverage for long-term compounding.
Constraints Limitations
The main constraint is evidentiary: missing historical growth and segment data prevent confirmation of a durable scaling model versus peers with clearer track records.
Negative ROIC signals that current economics may cap reinvestment effectiveness, which structurally limits the pace at which revenue can compound over time.
The absence of visible R&D or capex intensity makes it difficult to assess whether the company has the investment base needed for sustained expansion.
Compared with peers that have proven commercialization and repeatable growth, TPST remains constrained by limited proof of scalable revenue durability.
Overall Score
TPST’s long-term growth capacity appears structurally weak because the available metrics show negative capital efficiency and little evidence of repeatable, scalable revenue compounding versus peers.
Score Driver: Negative Capital Efficiency
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Tempest Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
